These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 16049200)

  • 1. Lack of effect of pravastatin on cerebral blood flow or parenchymal volume loss in elderly at risk for vascular disease.
    ten Dam VH; Box FM; de Craen AJ; van den Heuvel DM; Bollen EL; Murray HM; van Buchem MA; Westendorp RG; Blauw GJ;
    Stroke; 2005 Aug; 36(8):1633-6. PubMed ID: 16049200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pravastatin decreases wall shear stress and blood velocity in the internal carotid artery without affecting flow volume: results from the PROSPER MRI study.
    Box FM; van der Grond J; de Craen AJ; Palm-Meinders IH; van der Geest RJ; Jukema JW; Reiber JH; van Buchem MA; Blauw GJ;
    Stroke; 2007 Apr; 38(4):1374-6. PubMed ID: 17332443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decline in total cerebral blood flow is linked with increase in periventricular but not deep white matter hyperintensities.
    ten Dam VH; van den Heuvel DM; de Craen AJ; Bollen EL; Murray HM; Westendorp RG; Blauw GJ; van Buchem MA
    Radiology; 2007 Apr; 243(1):198-203. PubMed ID: 17329688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher Visit-to-Visit Low-Density Lipoprotein Cholesterol Variability Is Associated With Lower Cognitive Performance, Lower Cerebral Blood Flow, and Greater White Matter Hyperintensity Load in Older Subjects.
    Smit RA; Trompet S; Sabayan B; le Cessie S; van der Grond J; van Buchem MA; de Craen AJ; Jukema JW
    Circulation; 2016 Jul; 134(3):212-21. PubMed ID: 27436880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function.
    Wassmann S; Faul A; Hennen B; Scheller B; Böhm M; Nickenig G
    Circ Res; 2003 Oct; 93(9):e98-103. PubMed ID: 14551237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER).
    Packard CJ; Ford I; Robertson M; Shepherd J; Blauw GJ; Murphy MB; Bollen EL; Buckley BM; Cobbe SM; Gaw A; Hyland M; Jukema JW; Kamper AM; Macfarlane PW; Perry IJ; Stott DJ; Sweeney BJ; Twomey C; Westendorp RG;
    Circulation; 2005 Nov; 112(20):3058-65. PubMed ID: 16275871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
    Sattar N; Murray HM; McConnachie A; Blauw GJ; Bollen EL; Buckley BM; Cobbe SM; Ford I; Gaw A; Hyland M; Jukema JW; Kamper AM; Macfarlane PW; Murphy MB; Packard CJ; Perry IJ; Stott DJ; Sweeney BJ; Twomey C; Westendorp RG; Shepherd J;
    Circulation; 2007 Feb; 115(8):981-9. PubMed ID: 17283264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Volume measurement of cerebral blood flow: assessment of cerebral circulatory arrest.
    Schöning M; Scheel P; Holzer M; Fretschner R; Will BE
    Transplantation; 2005 Aug; 80(3):326-31. PubMed ID: 16082327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between cardiac function and resting cerebral blood flow: MRI measurements in healthy elderly subjects.
    Henriksen OM; Jensen LT; Krabbe K; Larsson HB; Rostrup E
    Clin Physiol Funct Imaging; 2014 Nov; 34(6):471-7. PubMed ID: 24314236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Measurement of cerebral blood flow in normal subjects by phase contrast MR imaging].
    Kashimada A; Machida K; Honda N; Mamiya T; Takahashi T; Kamano T; Inoue Y; Osada H
    Nihon Igaku Hoshasen Gakkai Zasshi; 1994 Oct; 54(12):1116-25. PubMed ID: 9261191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal relationship between cerebral small-vessel disease and cerebral blood flow: the second manifestations of arterial disease-magnetic resonance study.
    van der Veen PH; Muller M; Vincken KL; Hendrikse J; Mali WP; van der Graaf Y; Geerlings MI;
    Stroke; 2015 May; 46(5):1233-8. PubMed ID: 25804924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective study of pravastatin in the elderly at risk: new hope for older persons.
    Shepherd J
    Am J Geriatr Cardiol; 2004; 13(3 Suppl 1):17-24. PubMed ID: 15133425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pravastatin improves cerebral vasomotor reactivity in patients with subcortical small-vessel disease.
    Sterzer P; Meintzschel F; Rösler A; Lanfermann H; Steinmetz H; Sitzer M
    Stroke; 2001 Dec; 32(12):2817-20. PubMed ID: 11739979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Total cerebral blood flow and mortality in old age: a 12-year follow-up study.
    Sabayan B; van der Grond J; Westendorp RG; Jukema JW; Ford I; Buckley BM; Sattar N; van Osch MJ; van Buchem MA; de Craen AJ
    Neurology; 2013 Nov; 81(22):1922-9. PubMed ID: 24174588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In search for genetic determinants of clinically meaningful differential cardiovascular event reduction by pravastatin in the PHArmacogenetic study of Statins in the Elderly at risk (PHASE)/PROSPER study.
    Postmus I; Johnson PC; Trompet S; de Craen AJ; Slagboom PE; Devlin JJ; Shiffman D; Sacks FM; Kearney PM; Stott DJ; Buckley BM; Sattar N; Ford I; Westendorp RG; Jukema JW
    Atherosclerosis; 2014 Jul; 235(1):58-64. PubMed ID: 24816038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of withdrawal of pravastatin therapy on C-reactive protein and low-density lipoprotein cholesterol.
    van der Harst P; Asselbergs FW; Hillege HL; Bakker SJ; Voors AA; van Veldhuisen DJ; van Gilst WH;
    Am J Cardiol; 2007 Nov; 100(10):1548-51. PubMed ID: 17996517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.
    LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease)
    Lancet; 2002 Apr; 359(9315):1379-87. PubMed ID: 11978335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemoglobin, hematocrit, and changes in cerebral blood flow: the Second Manifestations of ARTerial disease-Magnetic Resonance study.
    van der Veen PH; Muller M; Vincken KL; Westerink J; Mali WP; van der Graaf Y; Geerlings MI;
    Neurobiol Aging; 2015 Mar; 36(3):1417-23. PubMed ID: 25618615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of statin treatment in elderly people: extended follow-up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER).
    Lloyd SM; Stott DJ; de Craen AJ; Kearney PM; Sattar N; Perry I; Packard CJ; Briggs A; Marchbank L; Comber H; Jukema JW; Westendorp RG; Trompet S; Buckley BM; Ford I
    PLoS One; 2013; 8(9):e72642. PubMed ID: 24023757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.